以色列 - 英文 - Ministry of Health

bayer israel ltd - hypericum perforatum - film coated tablets - hypericum perforatum 612 mg - symptoms of mild to moderate depression. treatment is recommended for up to 24 weeks.

以色列 - 英文 - Ministry of Health

unipharm ltd, israel - valsartan - tablets - valsartan 160 mg - valsartan - for treatment of hypertension. valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

以色列 - 英文 - Ministry of Health

unipharm ltd, israel - valsartan - tablets - valsartan 80 mg - valsartan - for treatment of hypertension.valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

以色列 - 英文 - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; magnesium chloride hexahydrate 0.051 g/l; lactic acid as sodium 1.68 g/l; sodium bicarbonate 2.10 g/l; glucose monohydrate (as anhydrous) 13.6 g/l; calcium chloride dihydrate 0.184 g/l - sodium chloride - sodium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure severe water retention severe electrolyte imbalance drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.

以色列 - 英文 - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; glucose monohydrate (as anhydrous) 22.7 g/l; calcium chloride dihydrate 0.184 g/l; lactic acid as sodium 1.68 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium bicarbonate 2.10 g/l - sodium chloride - sodium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure severe water retention severe electrolyte imbalance drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.

以色列 - 英文 - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; magnesium chloride hexahydrate 0.051 g/l; calcium chloride dihydrate 0.184 g/l; sodium bicarbonate 2.10 g/l; glucose monohydrate (as anhydrous) 38.6 g/l; lactic acid as sodium 1.68 g/l - calcium chloride - calcium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure; severe water retention; severe electrolyte imbalance; drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.

以色列 - 英文 - Ministry of Health

teva israel ltd - chlorpheniramine maleate; dextromethorphan hydrobromide; paracetamol; pseudoephedrine hydrochloride - caplets - paracetamol 500 mg; chlorpheniramine maleate 2 mg; pseudoephedrine hydrochloride 30 mg; dextromethorphan hydrobromide 15 mg - paracetamol - for the relief of cold, cough and nasal congestion associated with fever and pain, for night care.

以色列 - 英文 - Ministry of Health

rafa laboratories ltd - nimesulide - caplets - nimesulide 100 mg - nimesulide - nimesulide - acute pain.primary dysmenorrhea.

以色列 - 英文 - Ministry of Health

unipharm ltd, israel - simvastatin - film coated tablets - simvastatin 20 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvacor is indicated to: reduce the risk of total mortality by reducing coronary death reduce the risk of non-fatal myocardial infarction reduce the risk for undergoing myocardial revascularization procedures.reduce the risk of stroke and transient ischemic attacks (tia).hyperlipidemia: simvacor is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvacor therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios.homozygous familial hypercholesterolemia: simvacor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hypertrigly

以色列 - 英文 - Ministry of Health

unipharm ltd, israel - simvastatin - film coated tablets - simvastatin 10 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvacor is indicated to: reduce the risk of total mortality by reducing coronary death reduce the risk of non-fatal myocardial infarction reduce the risk for undergoing myocardial revascularization procedures. reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvacor is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvacor therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvacor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hypertri